Givaudan Active Beauty introduces Neoporyl™, an active ingredient that reduces the size of enlarged pores by targeting the biological root causes of parakeratosis, an alteration of the epidermal structure, and dermis fragility. This new active is crafted by biocatalysis to offer proven efficacy against enlarged pores in just one week.
Beauty consumers of every age, gender and skin type commonly complain about enlarged pores. Perceived as a sign of premature aging, pore size has become as much of a concern as fine lines and wrinkles. The importance of this issue for skin care consumers is such that a new term has been coined to describe a fixation with pore size: “Porexia.”
Strongly driven by genetics[1] and environmental factors, enlarged pores are caused by two main factors, parakeratosis and dermis fragility. Neoporyl™ effectively counteracts both of these key biological causes.
Mathias Fleury, Head of the Actives category for Active Beauty, said, “Our experts in Skin Physiology and White biotechnology have designed Neoporyl™, an innovative complex based on a biomimetic source of energy and key amino acids to address the biological phenomena of parakeratosis and skin fragility. Our active ingredient is able to limit hyperdifferentiation in the epidermis, reduce nucleated cell density in the stratum corneum, restore collagen production in the fragile dermis, and boost mature collagen and decorin production.”
Clinical tests have demonstrated a significant reduction of pore size in Caucasian women within just two weeks for all volunteers, regardless of age range and with increasing efficacy during the two-month trial period, down -24% versus the placebo. Similar benefits were perceived among Asian men, with a significant effect on pore size in just one week, up to 2.4× better than the placebo with an additional improvement of the skin appearance.
To learn more about NeoporylTM, we invite you to watch our video:
Note that Neoporyl™ is running for a C&T Alle Awards in the Active Beauty / Feel Good Beauty division!
[1] Wang S. et al. - J Investig Dermatol Symp Proc. 2018;19(2):S101-S102
Disclaimer:
The above paid-for content was produced by and posted on behalf of the Sponsor. Content provided is generated solely by the Sponsor or its affiliates, and it is the Sponsor’s responsibility for the accuracy, completeness and validity of all information included. Cosmetics & Toiletries takes steps to ensure that you will not confuse sponsored content with content produced by Cosmetics & Toiletries and governed by its editorial policy.
